We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Acadia Pharmaceuticals has terminated development of pimavanserin for major depressive disorder (MDD) after the drug failed to hit trials in this setting.
According to the National Institute of Mental Health, MDD affects approximately 16 million adults in the U.S. with approximately 2.5 million adults treated with adjunctive therapy.